Dennis Greenslade - Concepedia

Author

Dennis Greenslade

Sanofi (United States)

Also Known As

D Greenslade, Dennis Greenslade

Publications

791

Citations

H-Index

Concepts

All Affiliations

Sanofi (United States)Sanofi (Turkey)Sanofi (United Kingdom)

About

Dennis Greenslade is an author at Sanofi (United States) specializing in pharmacology, medicine, and pharmacokinetics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	610
2	Biochemistry	2	2	148
3	Engineering	1	1	35
4	Natural Sciences	1	1	35
5	Chemical Engineering	1	1	35

Dennis Greenslade

Publications

786

Citations

H-Index

Page 1

	Year	Citations
Clinical pharmacokinetics of oxaliplatin: a critical review. Martin A. Graham, G. Lockwood, Dennis Greenslade, PubMed Molecular PharmacologyOncologyTumor MicroenvironmentCritical ReviewMedicine	2000	459
Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: application to clinical pharmacokinetic studies with oxaliplatin James Gilmour Morrison, Peter C. White, Sophie McDougall, Journal of Pharmaceutical and Biomedical Analysis Therapeutic Drug MonitoringClinical Pharmacokinetic StudiesBiochemistryMedicineBioanalysis	2000	113
Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function Chris H. Takimoto, Martin A. Graham, G. Lockwood, Clinical Cancer Research	2007	67
Analysis of Toxicokinetic Data Using NONMEM: Impact of Quantification Limit and Replacement Strategies for Censored Data Jeremy Hing, Steven G. Woolfrey, Dennis Greenslade, Journal of Pharmacokinetics and Pharmacodynamics	2001	50
Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial Martin A. Graham, Suresh Senan, Hernani Robin, Cancer Chemotherapy and Pharmacology Pharmacological StudyMedicineDose-escalation StrategyRetrospective AnalysisToxicology	1997	38
Laboratory model for the biosynthesis of vallesamine, apparicine, and related alkaloids A. Ian Scott, Chun‐Hong Yeh, Dennis Greenslade Journal of the Chemical Society Chemical Communications A. I. ScottEngineeringSecondary MetaboliteChemistrySpectra-structure Correlation	1978	35
Is Mixed Effects Modeling or Naïve Pooled Data Analysis Preferred for the Interpretation of Single Sample per Subject Toxicokinetic Data? Jeremy Hing, Steven G. Woolfrey, Dennis Greenslade, Journal of Pharmacokinetics and Pharmacodynamics Mixed EffectsPsychiatrySingle SampleSubject Toxicokinetic DataStatistics	2001	24

Page 1